OnabotulinumtoxinA Wear-off Phenomenon in the Treatment of Chronic Migraine.

Most patients with CM receiving onabotA experience wear-off. Clinicians may consider increasing the units used from the treatment onset to reduce the frequent need for bridging therapies.